229 patents
Page 5 of 12
Utility
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
5 Jul 22
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Xingxing Zang
Filed: 20 Dec 19
Utility
Reversibly Switchable Photoacoustic Imaging Systems and Methods
9 Jun 22
Reversibly switchable photoacoustic tomography (RS-PAT), a photoacoustic technique with enhanced sensitivity and resolution, is disclosed.
Vladislav V. Verkhusha, Andrii A. Kaberniuk, Lihong Wang, Junjie Yao, Lei Li
Filed: 10 Nov 21
Utility
Engineered PD-1 variants
7 Jun 22
Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof.
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Filed: 9 May 17
Utility
Monoclonal Antibodies for Prevention and Treatment of Herpes Simplex Viral Infections
26 May 22
Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.
Betsy C. HEROLD, Garnett KELSOE, Masayuki KURAOKA, Clare BURN, William R. Jacobs, Jr.
Filed: 19 Mar 20
Utility
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
24 May 22
The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides.
Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel, III
Filed: 17 May 17
Utility
Transdermal Delivery Formulations
12 May 22
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 26 Jan 22
Utility
Transdermal Delivery Formulations
12 May 22
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 30 Dec 21
Utility
Treatment of Cancer Using Recall Antigens Delivered by Attenuated Bacteria
28 Apr 22
Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Claudia Gravekamp
Filed: 16 Nov 21
Utility
Stem-loop Compositions and Methods for Inhibiting Vascular Endothelial Growtn Factor
31 Mar 22
The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A).
Carl ERICKSON, Christopher P. RUSCONI, Matthew LEVY, Keith E. MAIER, Sarah E. THACKER, Derek PARKS
Filed: 10 Jan 20
Utility
Engineered PD-1 Variants
31 Mar 22
Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof.
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Filed: 3 May 21
Utility
Passive Transfer of Immunity Using Recombinant Herpes Simplex Virus 2 (HSV-2) Vaccine Vectors
24 Mar 22
Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.
Betsy HEROLD, William JACOBS, JR., Pablo A. GONZALEZ-MUNOZ, Christopher PETRO
Filed: 3 Jan 20
Utility
Attb Cell Line, Transgenic Cell Lines Derived Therefrom, and Methods of Making the Same
24 Mar 22
A genetically modified mammalian cell and genetically modified mammalian cell line comprise a recombination sequence inserted in a target locus on a chromosome of the mammalian cell genome, wherein the recombination sequence comprises Bxb1attB sequence from Mycobacterium smegmatis.
William R. Jacobs, Jr., Lawrence Leung, Regy Lukose, Anna Paula de Oliveira
Filed: 24 Sep 21
Utility
Broad spectrum viral inhibitor
22 Mar 22
Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses.
Steven C. Almo, Tyler Grove, Anthony Gizzi, Craig E. Cameron, James J. Arnold
Filed: 21 Aug 18
Utility
Microbial Hyperswarmers and Uses Thereof
17 Mar 22
Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.
Sridhar Mani, Libusha Kelly, Hao Li
Filed: 8 Oct 21
Utility
HHLA2 as a novel inhibitor of human immune system and uses thereof
1 Mar 22
Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
Xingxing Zang
Filed: 5 Sep 18
Utility
Monoclonal antibodies and cocktails for treatment of Ebola infections
22 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
Mutant Variants of PD-1 Receptor with Selective Binding to PD-L1 and Uses Thereof
17 Feb 22
Disclosed are human Programmed Cell Death-1 (PD-1) receptor mutants having selectivity for PD-L1 compared to PD-L2, methods of obtaining the mutants, and uses of the mutants for treatment and imaging.
Andras Fiser, Rojan Shrestha, Steven C. Almo, Sarah, C. Garrett
Filed: 18 Sep 19
Utility
Monoclonal antibodies and cocktails for treatment of Ebola infections
8 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
Monoclonal antibodies and cocktails for treatment of Ebola infections
8 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
Small Molecule Inhibition of Sulfotransferase SULT1A3
27 Jan 22
Provided herein are small molecule compounds and methods inhibiting human sulfotransferase 1A3 (SULT1A3) using these small molecule compounds.
Alexander Deiters, Kristie E. Darrah, Mary Frances Cacace, Ian Cook, Thomas Leyh, Ting Wang
Filed: 10 Dec 19